OrsoBio raises $67 million in Series B funding
OrsoBio, a clinical-stage biopharmaceutical company developing treatments for obesity and related metabolic disorders like type 2 diabetes, NASH (nonalcoholic steatohepatitis), and severe dyslipidemias, raised $67 … Read more